Literature DB >> 18500522

Human concentrative nucleoside transporter 3 is a determinant of fludarabine transportability and cytotoxicity in human renal proximal tubule cell cultures.

Adam N Elwi1, Vijaya L Damaraju, Michelle L Kuzma, Stephen A Baldwin, James D Young, Michael B Sawyer, Carol E Cass.   

Abstract

PURPOSE: Interpatient variability in renal elimination of fludarabine (9-beta-D-arabinosyl-2-fluoroadenine) by renal human nucleoside transporters (hNTs) may contribute to unpredictable toxicities including rare nephrotoxicities. This study assessed relationships between hNT levels and fludarabine uptake and cytotoxicity in cultures of human renal proximal tubule cells (hRPTCs) that produce multiple transporter types.
METHODS: hRPTC cultures were established from ten different individuals and their hNT characteristics were assessed by measuring RNA expression by TaqMantrade mark reverse transcriptase polymerase chain reaction, protein abundance by quantitative immunoblotting of cell surface protein preparations, and uptake by radiolabeled nucleoside uptake assays. Fludarabine cytotoxicity against hRPTC cultures was quantified using methoxyphenyl tetrazolium inner salt (MTS) assays.
RESULTS: RNA, protein and activities for human equilibrative NT 1 (hENT1) and 2 (hENT2) and human concentrative NT 3 (hCNT3) were identified in cultures of hRPTCs from ten different individuals. Significant differences in hCNT3 activities were exhibited among hRPTC cultures and correlated positively with cell surface levels of hCNT3 protein, but did not correlate with hCNT3 mRNA levels.
CONCLUSIONS: Observed differences in hCNT3-mediated uptake activities, hNT-mediated fludarabine uptake activities, and fludarabine cytotoxicities correlated positively with each other, suggesting that hCNT3 is a primary determinant of fludarabine uptake and cytotoxicity in hRPTC cultures. Variations in hCNT3 abundance in renal proximal tubules, and hence nucleoside reabsorption, may explain interpatient variability in fludarabine's pharmacokinetics and toxicities.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18500522     DOI: 10.1007/s00280-008-0739-1

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  6 in total

1.  Impacts of blood-brain barrier in drug delivery and targeting of brain tumors.

Authors:  Yadollah Omidi; Jaleh Barar
Journal:  Bioimpacts       Date:  2012-02-02

2.  Role of OCT2 and MATE1 in renal disposition and toxicity of nitidine chloride.

Authors:  L P Li; F F Song; Y Y Weng; X Yang; K Wang; H M Lei; J Ma; H Zhou; H D Jiang
Journal:  Br J Pharmacol       Date:  2016-07-09       Impact factor: 8.739

3.  Inhibition of histone deacetylase 7 reverses concentrative nucleoside transporter 2 repression in colorectal cancer by up-regulating histone acetylation state.

Authors:  Chaonan Ye; Kun Han; Jinxiu Lei; Kui Zeng; Su Zeng; Haixing Ju; Lushan Yu
Journal:  Br J Pharmacol       Date:  2018-10-04       Impact factor: 8.739

4.  Identification and characterization of proximal promoter polymorphisms in the human concentrative nucleoside transporter 2 (SLC28A2).

Authors:  Sook Wah Yee; James E Shima; Stephanie Hesselson; Loan Nguyen; Sarah De Val; Rachel J Lafond; Michiko Kawamoto; Susan J Johns; Doug Stryke; Pui-Yan Kwok; Thomas E Ferrin; Brian L Black; David Gurwitz; Nadav Ahituv; Kathleen M Giacomini
Journal:  J Pharmacol Exp Ther       Date:  2008-12-19       Impact factor: 4.030

5.  Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  E Mohanan; J C Panetta; K M Lakshmi; E S Edison; A Korula; N A Fouzia; A Abraham; A Viswabandya; V Mathews; B George; A Srivastava; P Balasubramanian
Journal:  Bone Marrow Transplant       Date:  2017-05-08       Impact factor: 5.483

Review 6.  The Transporter-Mediated Cellular Uptake and Efflux of Pharmaceutical Drugs and Biotechnology Products: How and Why Phospholipid Bilayer Transport Is Negligible in Real Biomembranes.

Authors:  Douglas B Kell
Journal:  Molecules       Date:  2021-09-16       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.